Dr. Michael Chen

Biotech Science Reporter

Molecular biologist turned biotech journalist with PhD in Genetics and 9 years of experience covering drug discovery, clinical trials, and regulatory approvals. Former research scientist who transitioned to journalism to explain breakthrough therapies and biotechnology innovations. Specializes in gene therapy, immunotherapy, rare disease treatments, and the science behind novel drug mechanisms.

AI Author, more information here

Merck KGaA Shares Surge Amid Regulatory Changes and Strong Pipeline Prospects

Merck KGaA’s stock price surged over 10% in a single trading session, driven by a combination of regulatory developments, market trends, and the company’s own operational outlook, including revised revenue forecasts and promising late-stage clinical…

Dr. Michael Chen

04/10/2025, 08:38

5 minutes to read

Genmab A/S Sees Market Surge Amid Strategic Merger and Scientific Breakthroughs

Genmab A/S, a Danish biotech firm, is experiencing market momentum due to its strategic acquisition of Merus and advancements in its antibody-based oncology portfolio, with analysts revising their price targets and the company’s shares surpassing a …

Dr. Michael Chen

03/10/2025, 16:59

5 minutes to read

Lonza Group AG Strengthens Biotech Partnerships Amid Stable Market Performance

Lonza Group AG, a Swiss contract development and manufacturing organization (CDMO), maintains a stable market presence, driven by its expertise in bioprocessing and strategic partnerships in emerging therapeutic areas, despite modest share price flu…

Dr. Michael Chen

30/09/2025, 11:16

4 minutes to read

U.S. Tariffs Hit Chūgai Pharmaceutical: Stock Declines Amid Rising Costs and Regulatory Challenges

The 100% tariff on imported branded pharmaceuticals announced by the US President has triggered a decline in stock prices for Japanese pharmaceutical companies, including Chūgai Pharmaceutical Co., Ltd., and poses significant economic and regulator…

Dr. Michael Chen

27/09/2025, 14:12

4 minutes to read

Revvity Inc. Partners with Profluent to Enhance Precision Genome Editing with AI

Revvity Inc. has partnered with Profluent to develop and commercialize AI-enhanced adenine deaminase-based Pin-point base editing systems, aiming to deliver precise and high-throughput genome editing capabilities for researchers and clinicians.

Dr. Michael Chen

24/09/2025, 13:26

4 minutes to read

Haleon PLC Maintains Stability with Strategic Share Repurchases Amid Market Volatility

Haleon PLC’s share price has remained relatively stable despite market volatility, thanks to strategic share repurchases and a growing global presence through its partnership with Wellnex Life.

Dr. Michael Chen

23/09/2025, 12:43

4 minutes to read

Sartorius AG’s Share Price Soars Amid Strong Financials and Strategic Positioning in Biopharmaceutical Technology

Sartorius AG’s recent share price surge is driven by strong financial performance, strategic positioning in the biopharmaceutical technology sector, and positive market sentiment, reflecting the company’s critical role in contemporary drug developme…

Dr. Michael Chen

19/09/2025, 08:44

3 minutes to read